Novo Nordisk stock tumbles Monday to its lowest point in nearly 5 years. Here's why
Key Takeaways Novo Nordisk shares plunged Monday after the Ozempic and Wegovy maker's newest drug trial results came in short of expectations.Novo Nordisk's CagriSema, its next-generation weight-loss drug, led patients to lose less weight over 84 weeks...
Investopedia